KYTRIL
LOE ApproachingNDAORALTABLET
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYTRIL (granisetron) is an oral small-molecule 5-HT3 receptor antagonist approved in 1995 for chemotherapy-induced nausea and vomiting (CINV). It blocks serotonin signaling in the chemoreceptor trigger zone and GI tract to prevent CINV in cancer patients undergoing chemotherapy. The drug is a foundational antiemetic in oncology support care.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on lifecycle extension and cost-containment strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Started Apr 2007
171 enrolled
Post-Operative Nausea and Vomiting
Career Relevance
KYTRIL roles are concentrated in commercial and access functions, not growth-stage innovation. Career progression here requires expertise in mature-market defense, generic competition, and payer negotiations rather than launch or expansion.
Brand Manager
Worked on KYTRIL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.